Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Review Article

SRP. 2020; 11(6): 112-123

Review of Ameloblastoma Case

Bayu Indra Sukmana, Herlina Uinarni, Huldani, Muhammad Nasrum Massi, Bachtiar Murtala, Fiory Dioptis Putriwijaya, Harry Darmawan, Harun Achmad.

Ameloblastoma is a benign epithelial neoplasm and ranges from 10% of the entire odontogenic tumor. Ameloblastoma is characterized by a slow growth pattern and can grow to a very large size and cause severe facial deformities. These tumors are most common at the age of the third and fourth decades, and most often occur in the posterior mandibular, especially in the third molar tooth, as well as associated with the impacted follicular or dental cyst. Classification of Ameloblastoma According to WHO distinguishable into benign ameloblastoma which include: (1) solid/multicystic ameloblastoma, (2) unicystic Ameloblastoma, (3) the peripheral (or extraosseous) ameloblastoma, (4) the desmoplastic ameloblastoma and malignant ameloblastoma based on the frequency sequence which includes: (a) metastasizing ameloblastoma, (b) Primary ameloblastic carcinoma, (c) Secondary intraosseous ameloblastic carcinoma, (d) secondary peripheral ameloblastic carcinoma. A radiological examination that can be conducted to diagnose ameloblastoma is plain photo, CT Scan and MRI. The image of Meloblastoma radiography may vary. Some of the depictions of lusent lesions are firmly, unilocular, well-orticated, which often relate to Corona tooth impacted or no eruption, so that it cannot be distinguished by odontogenic keratosis and dentigerous cysts on radiography. Some of the other, multilocular, internal septa and honey comb or soap appearance bubbles are often similar to the large odontogenic keratosis. However, only histopatological findings can help to determine the malignant tumors and the alteration of carcinomatose.

Key words: Ameloblastoma, Neoplasma, Odontogenic tumor

Similar Articles

Photothermal scaffolds/surfaces for regulation of cell behaviors.
Qu Y, Lu K, Zheng Y, Huang C, Wang G, Zhang Y, Yu Q
Bioactive materials. 2022; 8(): 449-477

Measuring Sulfatase Expression and Invasion in Glioblastoma.
Wade A, Engler JR, Tran VM, Phillips JJ
Methods in molecular biology (Clifton, N.J.). 2022; 2303(): 415-425

Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor.
Kim HS, Lee SJ, Lee DY
Bioactive materials. 2022; 8(): 35-48

Overcoming the obstacles of current photodynamic therapy in tumors using nanoparticles.
Lee D, Kwon S, Jang SY, Park E, Lee Y, Koo H
Bioactive materials. 2022; 8(): 20-34

Synergistic enhancement of immunological responses triggered by hyperthermia sensitive Pt NPs NIR laser to inhibit cancer relapse and metastasis.
Yu J, Liu S, Wang Y, He X, Zhang Q, Qi Y, Zhou D, Xie Z, Li X, Huang Y
Bioactive materials. 2022; 7(): 389-400

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.

ScopeMed Web Sites